Straits Times Index
3,338.98 -9.89 (-0.30%) Nikkei
38,837.46 -85.54 (-0.22%) Hang Seng
18,444.11 +41.11 (+0.22%) FTSE 100
8,216.18 -46.57 (-0.56%) Bitcoin USD
68,890.62 -266.67 (-0.39%) CMC Crypto 200
1,446.56 -0.59 (-0.04%)
DIAGNOS Inc. (ADK.V)
| Previous close | 0.3100 |
| Open | 0.3050 |
| Bid | 0.2950 x 0 |
| Ask | 0.3000 x 0 |
| Day's range | 0.2950 - 0.3050 |
| 52-week range | 0.2300 - 0.5900 |
| Volume | |
| Avg. volume | 82,089 |
| Market cap | 23.332M |
| Beta (5Y monthly) | -0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
DIAGNOS celebrates the launch of Labtician’s new screening service for diabetic retinopathy in Ontario and renews its distribution agreement
BROSSARD, Quebec, May 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its FLAIRE platform based on Artificial Intelligence (AI), is thrilled to announce the renewal of its distribution agreement with Labtician, a leading provider of medical supplies and equipment, for the Canadian territory. This renewed distribution agreement comes after the final integration of DIAGNOS’
- GlobeNewswire
DIAGNOS Announces Closing of First Tranche of Private Placement
BROSSARD, Quebec, May 09, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through the use of Artificial Intelligence (AI) technologies, announces the closing of a first tranche of 1,125,000 units (each a “Unit”) issued at a price of $0.28 per Unit, for gross proceeds of $315,000, as part of a non-brokered private placement of up to 5,357,142 units, for gross proceeds of up to $1,500,0
- GlobeNewswire
DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024
BROSSARD, Quebec, May 06, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Company”) (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critical health issues, in collaboration with ETS, École de Technologie Supérieure, is proud to announce its participation in the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting. DIAGNOS will showcase its latest advancements in artificial intelligence applied to retinal imagi
